Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with 99mTc-peptide-ZHER2:342

Nuclear Medicine and Biology

Volumn 42, Issue 6, 2015, Pages 541-546

  Zhang, Jingmian ^a   Zhao, Xinming ^a   Wang, Shijie ^a   Wang, Na ^a   Han, Jingya ^a   Jia, Lizhuo ^a   Ren, Xiuchun ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Affibody molecule; HER2; Molecular imaging; Trastuzumab; Tumor response

Indexed keywords

ALANINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCINE; PEPTIDE DERIVATIVE; SODIUM CHLORIDE; TECHNETIUM 99M; TRASTUZUMAB; ANTINEOPLASTIC AGENT; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG MONITORING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PROTEIN EXPRESSION; RADIATION MEASUREMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; ENZYME IMMUNOASSAY; FEMALE; IMAGE PROCESSING; IMMUNOLOGY; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGOPEPTIDES; ORGANOTECHNETIUM COMPOUNDS; OVARIAN NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84928827128     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2015.02.002     Document Type: Article

References (35)

1. Pohlmann P.R., Mayer I.A., Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009, 15:7479-7491. [PubMed: 20008848].
2. Verri E., Guglielmini P., Puntoni M., Perdelli L., Papadia A., Lorenzi P., et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Oncology 2005, 68:154-161. [PubMed: 16020953].
3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics. CA Cancer J Clin 2008, 58:71-96. [PubMed:11287387].
4. Breedlove G., Busenhart C. Screening and detection of ovarian cancer. J Midwifery Womens Health 2005, 50:51-54. [PubMed:15637515].
5. Di Lauro V., Torrisi E., Bidoli E., Quitadamo D., Cecco S., Veronesi A. Trastuzumab and gemcitabine in pretreated HER2 overexpressing metastatic breast cancer patients: retrospective analysis of our series. J Oncol 2012, 2012:198412. [PubMed: 22536237].
6. Fabi A., Di Benedetto A., Metro G., Perracchio L., Nistico C., Di Filippo F., et al. HER2 Protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011, 17:2055-2064. [PubMed: 21307144].
7. Pectasides D., Gaglia A., Arapantoni-Dadioti P., Bobota A., Valavanis C., Kostopoulou V., et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 2006, 26:647-653. [PubMed: 16739334].
8. Zidan J., Dashkovsky I., Stayerman C., BasherW Cozacov C., Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005, 93:552-556. [PubMed: 16106267].
9. McLarty K., Cornelissen B., Cai Z., Scollard D.A., Costantini D.L., Done S.J., et al. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 2009, 50:1340-1348. [PubMed: 19617342].
10. 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging 2009, 36:81-93. [PubMed: 18712381].
11. Adams G.P., Schier R., Marshall K., Wolf E.J., McCall A.M., Marks J.D., et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998, 58:485-490. [PubMed: 9458094].
12. 2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004, 17:315-323. [PubMed: 15187222].
13. Robinson M.K., Doss M., Shaller C., Narayanan D., Marks J.D., Adler L.P., et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005, 65:1471-1478. [PubMed: 15735035].
14. 111In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 2005, 32:51-58. [PubMed: 15691661].
15. HER2:342, a potential agent for imaging of HER2 expression in malignant tumors. Int J Mol Med 2007, 20:397-404. [PubMed: 17671747].
16. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 2006, 47:846-853. [PubMed: 16644755].
17. 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 2010, 37:1356-1367. [PubMed: 21030858].
18. 177Lu-labeled HER2-specific affibody molecule. Cancer Res 2007, 67:2773-2782. [PubMed: 17363599].
19. Orlova A., Tran T.A., Ekblad T., Karlstrom A.E., Tolmachev V. (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging 2010, 37:260-269. [PubMed: 19771426].
20. Kramer-Marek G., Kiesewetter D.O., Martiniova L., Jagoda E., Lee S.B., Capala J. [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008, 35:1008-1018. [PubMed: 18157531].
21. 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 2007, 34:722-733. [PubMed: 17146656].
22. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging 2007, 34:1843-1853. [PubMed: 17565496].
23. 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 2008, 35:2245-2255. [PubMed: 18594815].
24. 99mTc-maEEE-ZHER2:342, an affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem 2007, 18:1956-1964. [PubMed: 17944527].
25. m labeled survivin mRNA antisense PNA and gene imaging in nude mice bearing lung carcinoma A549 xenografts. Clin J Nucl Med 2011, 31:339-343.
26. HER2:342 affibody molecule for in vivo molecular imaging. Br J Radiol 2014, 87:20130484. [PubMed: 24273251].
27. Wu Y., Soslow R.A., Marshall D.S., Leitao M., Chen B. HER2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol 2004, 95:570-575. [PubMed: 15581965].
28. Serrano-Olvera A., Duenas-Gonzalez A., Gallardo-Rincon D., Candelaria M., De la Garza-Salazar J. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2006, 32:180-190. [PubMed: 16483720].
29. Moelans C.B., de Weger R.A., Van der Wall E., van Diest P.J. Current technologies for HER2 testing in breast cancer. Crit Rev Oncol Hematol 2011, 80:380-392. [PubMed: 21273092].
30. Vogel C. Trastuzumab monotherapy. Breast Cancer Res Treat 2003, 81:S67-S68.
31. Charatan F. News feature: costly US anticancer drugs pose problems for doctors and patients. BMJ 2008, 337:a778. [PubMed: 18625596].
32. Smith-Jones P.M., Solit D.B., Akhurst T., Afroze F., Rosen N., Larson S.M. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004, 22:701-706. [PubMed: 15133471].
33. Behr T.M., Behe M., Wormann B. Trastuzumab and breast cancer. N Engl J Med 2001, 345:995-996. [PubMed: 11575295].
34. Steffen A.C., Wikman M., Tolmachev V., Adams G.P., Nilsson F.Y., Stahl S., et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm 2005, 20:239-248. [PubMed: 15989469].
35. 68Ga-labeled affibody molecules. J Nucl Med 2010, 51:892-897. [PubMed: 20484419].